ERAS — Recent News Coverage
All news mentioning ERAS in ESEN's AI-graded feed
News stories with ERAS as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on ERAS. See /coverage/ERAS for the 30-day aggregate.
MARKETS.BUSINESSINSIDER.COM
·
2026-07-27
LOW
BEARISH
CORR0.15
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
$ERAS
◈ ESEN AI
Erasca, Inc. (ERAS) faces a class action lawsuit with an August 10, 2026 application deadline, as announced by law firm Kahn Swick & Foti. This represents a governance or disclosure concern that typically signals shareh…
MARKETS.BUSINESSINSIDER.COM
·
2026-07-24
LOW
BEARISH
CORR-0.15
Kaplan Fox Reminds Erasca, Inc. (ERAS) Investors Seeking Recovery of the Lead Plaintiff Deadline on August 10, 2026
$ERAS
◈ ESEN AI
Erasca Inc. (ERAS) faces class action litigation with a lead plaintiff deadline of August 10, 2026. This announcement reflects potential shareholder grievances related to undisclosed material information or misrepresent…
SEEKINGALPHA.COM
·
2026-07-17
NEUTRAL
NEUTRAL
CORR0.35
Erasca: A Credible Rival To Revolution's Daroxonrasib, At A Cheaper Price Point (ERAS)
$ERAS
◈ ESEN AI
Erasca (ERAS) has emerged as a potential competitor to Revolution Medicines' daroxonrasib with its ERAS-0015 candidate, positioning itself at a lower cost basis. The comparison centers on clinical efficacy, manufacturin…
MANILATIMES.NET
·
2026-07-15
NEUTRAL
NEUTRAL
CORR0.35
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
$ERAS
◈ ESEN AI
ERAS completed an upsized equity offering of 36.1 million shares at $17.50 per share, raising approximately $632.5 million in gross proceeds. The company exercised the full underwriters' option, indicating robust instit…
INSIDERMONKEY.COM
·
2026-07-14
NEUTRAL
BULLISH
CORR0.42
Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results
$ERAS
◈ ESEN AI
Erasca (ERAS) posted a substantial single-day gain of 8.9% following disclosure of positive clinical trial outcomes for its RAS-mutant solid tumor therapeutic candidate. This represents a typical biotech catalyst event …
MANILATIMES.NET
·
2026-07-14
NEUTRAL
NEUTRAL
CORR0.15
Erasca Announces Pricing of Upsized Public Offering of Common Stock
$ERAS
◈ ESEN AI
Erasca (ERAS), a clinical-stage precision oncology company, announced the pricing of an upsized public offering at $17.50 per share, raising approximately $550 million in gross proceeds. The offering comprises 31.4 mill…
SEEKINGALPHA.COM
·
2026-07-13
NEUTRAL
NEUTRAL
CORR0.15
Erasca announces $500M common stock offering (ERAS:NASDAQ)
$ERAS
◈ ESEN AI
Erasca announced a $500M common stock offering with a $75M greenshoe option, raising capital for R&D and operational needs. This represents a significant dilution event for existing shareholders, typical of clinical-sta…
MANILATIMES.NET
·
2026-07-13
NEUTRAL
NEUTRAL
CORR0.15
Erasca Announces Proposed Public Offering of $500 Million of Common Stock
$ERAS
◈ ESEN AI
Erasca (ERAS), a clinical-stage precision oncology company, announced a $500 million public offering of common stock with an additional $75 million option for underwriters. This represents a dilutive capital raise typic…
MANILATIMES.NET
·
2026-07-13
NEUTRAL
BULLISH
CORR0.45
Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
$ERAS
$RVMD
◈ ESEN AI
Erasca has released updated Phase 1 clinical trial data for ERAS-0015, a pan-RAS molecular glue candidate targeting KRAS-mutant solid tumors. The trial demonstrated a 57% unconfirmed overall response rate (uORR) in seco…
MARKETS.BUSINESSINSIDER.COM
·
2026-07-13
LOW
BEARISH
CORR0.15
ERAS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
$ERAS
◈ ESEN AI
Erasca (ERAS) faces an August 10, 2026 deadline for investors to join an ongoing securities class action lawsuit, signaling continued legal and reputational headwinds for the biopharmaceutical firm. This type of litigat…
INSIDERMONKEY.COM
·
2026-06-11
NEUTRAL
BULLISH
CORR0.42
Erasca (ERAS) Receives Encouraging Expert Feedback on ERAS-0015 Clinical Trials
$ERAS
◈ ESEN AI
Erasca (ERAS) has reported favorable expert feedback regarding its ERAS-0015 clinical trial program, generating positive sentiment among market participants as of June 5. The encouraging data suggests the company's pipe…
EXPLORE OTHER FILTERS